

(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



10/527280



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022539 A1

(51) International Patent Classification⁷: C07D 211/22,
A61K 31/451, A61P 25/00, 9/00

Wilmington, DE 19850-5437 (US). WARWICK, Paul
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,
Wilmington, DE 19850-5437 (US).

(21) International Application Number:
PCT/SE2003/001399

(74) Agent: ASTRAZENECA AB, Global Intellectual Prop-
erty, S-151 85 Södertälje (SE).

(22) International Filing Date:
8 September 2003 (08.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202674-8 9 September 2002 (09.09.2002) SE
0301052-7 8 April 2003 (08.04.2003) SE

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): BERNSTEIN,
Peter [US/US]; AstraZeneca Wilmington, P.O. Box
15437, Wilmington, DE 19850-5437 (US). CACCIOLA,
Joseph [US/US]; AstraZeneca Wilmington, P.O. Box
15437, Wilmington, DE 19850-5437 (US). DEDINAS,
Robert [US/US]; AstraZeneca Wilmington, P.O. Box
15437, Wilmington, DE 19850-5437 (US). SHEN, Li-
hong [US/US]; AstraZeneca Wilmington, P.O. Box 15437,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NAPHTHYL ETHER COMPOUNDS AND THEIR USE



(57) Abstract: Compounds having the following structure wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ m and n are as defined in the speci-
fication, *in vivo*-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical
compositions and methods of treatment using the same.

WO 2004/022539 A1

INTERNATIONAL SEARCH REPORT

Rec'd PCT/PTO 08 MAR 2005
10/527280

International application No. 80
PCT/SE 03/01399

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 211/22, A61K 31/451, A61P 25/00, A61P 9/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, CHEM.ABS.DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2347423 A (MERCK SHARP & DOHME LIMITED), 6 Sept 2000 (06.09.00), claims 8,16-18, page 38, line 23 - line 26 --	1-11
X	J. Med. Chem., Volume 38, No. 8, 1995, Graeme I. Stevenson et al, "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist", pages 1264-1266 --	1-11
X	J. Med. Chem., Volume 41, No. 23, 1998, Graeme I. Stevenson et al, "4,4 Disubstituted Piperidine High-Affinity NK1, Antagonists: Structure-Activity Relationships and in Vivo Activity", pages 4623-4635 --	1-11

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 20 October 2003	Date of mailing of the international search report 21-10-2003
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer GERD STRANDELL/BS Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EE 03/01399

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT


Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9519344 A1 (MERCK SHARP & DOHME LIMITED), 20 July 1995 (20.07.95), the claims, page 18, line 12 - page 19, line 20 --	1-11
X	WO 9410165 A1 (MERCK SHARP & DOHME LIMITED), 11 May 1994 (11.05.94), the claims, page 20, line 16 - page 21, line 29 --	1-11
A	Bioorganic & Medicinal Chemistry Letters, Volume 12, No. 13. 8 July 2002, Jason M. Elliott et al, "4,4-Disubstituted Cyclohexylamine NK1 Receptor Antagonists.I", pages 1755-1758, page 1758, table 3, compound nos. 23,27 --	1-11
A	Bioorganic & Medicinal Chemistry Letters, Volume 12, No. 2, 2002, Thomas Ryckmans et al, "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants", pages 261-264 -- -----	1-11

INTERNATIONAL SEARCH REPORT

Information on  family members

06/09/03

International application No.

PCT/ 03/01399

Patent document cited in search report				Publication date		Patent family member(s)		Publication date	
GB	2347423	A	06/09/00	GB	0004167	D	00/00/00		
				GB	9904786	D	00/00/00		
				US	6136824	A	24/10/00		

WO	9519344	A1	20/07/95	AT	170174	T	15/09/98		
				AU	685212	B	15/01/98		
				AU	1390295	A	01/08/95		
				AU	6216594	A	11/10/94		
				CA	2180746	A	20/07/95		
				DE	69504300	D,T	29/04/99		
				EP	0690734	A	10/01/96		
				EP	0739336	A,B	30/10/96		
				ES	2120170	T	16/10/98		
				GB	9400542	D	00/00/00		
				JP	9507500	T	29/07/97		
				US	5760018	A	02/06/98		
				GB	9403072	D	00/00/00		

WO	9410165	A1	11/05/94	AT	188472	T	15/01/00		
				AU	678409	B	29/05/97		
				AU	5342994	A	24/05/94		
				DE	69327541	D,T	10/08/00		
				EP	0666856	A,B	16/08/95		
				ES	2141174	T	16/03/00		
				GB	9222633	D	00/00/00		
				JP	8502510	T	19/03/96		
				US	5620989	A	15/04/97		
				GB	9308962	D	00/00/00		
				GB	9313680	D	00/00/00		
				GB	9316112	D	00/00/00		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/01399

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **8-10**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☒ Claims Nos.: **1-5, 8, 9 all in part**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Box I:1

Claims 8-10 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions. These alleged effects must be well defined diseases or conditions.

Box I:2

The expression "a disease condition wherein antagonism of NK₁ receptors in combination with SRI activity is beneficial" in claims 8 and 9 may relate to a number of different disorders and conditions, which can not be clearly (Article 6 PCT) defined by this expression. Thus, the search has mainly been restricted to the diseases mentioned in claims 7, 10 and 11.

The scope of the claims 1-5, 8 and 9, in as far as the expression "in vivo-hydrolysable precursor(s) thereof" is concerned, is so unclear (Article 6 PCT) that a meaningful International Search is impossible with regard to this expression.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established will not be the subject of an international preliminary examination (Rule 66.1(e) PCT). This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.